Virios Therapeutics, Inc.
VIRI · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.00 | -0.00 | -1.80 |
| FCF Yield | -47.45% | -73.16% | -192.57% | -0.48% |
| EV / EBITDA | 1.21 | 2.47 | 0.00 | -81.60 |
| Quality | ||||
| ROIC | -4.14% | -4.77% | 0.00% | -242.37% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.21 | 1.06 | 0.43 | 0.71 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 14.02% | 46.71% | -965,423.51% | -12.12% |
| Safety | ||||
| Net Debt / EBITDA | 3.37 | 3.92 | 0.00 | 0.89 |
| Interest Coverage | -35.22 | -30.12 | -132.53 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |